Recent Updates
Recently added Catalysts

Connect Biopharma Holdings Limited

CNTBFDA catalysts, PDUFA dates & pipeline intelligence
$0.59
▼ -0.04 · -6.08%

Financials

Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Quarterly Cash
Unlock full CNTB financials and dilution scoring
Quarter by quarter figures, cash trend and dilution risk.
Institutional-grade data · Cancel anytime
52W LOW $0.5552W HIGH $3.82
Volume
365.98 K
Value Traded
222.44 K
Short % Float
21.87%
Days to Cover
4.2
-12.88%Week
-26.07%1 Month
-75%3 Month
-74.89%6 Month
-81.27%1 Year
-87.98%All Time

Cash Data

Unlock CNTB cash and runway
  • Monthly Burn
  • Burn Trend
  • Dilution Risk
  • SEC Filing

Key Stats

Market Cap
38.05 M
EPS (TTM)
-1.14
P/E Ratio
-
Ent. Value
18.56 M
Total Shares
64.49 M
Float Shares
17.51 M
Insiders
72.85%
Institutions
23.28%

Upcoming Catalysts

FDA decisions, readouts and PDUFA dates · scored by probability of approval

Catalyst Drug / Treatment Stage Prob. of Approval Description Drug Type Therapeutic Area Source
Unlock every CNTB catalyst date and PoA score
Every FDA decision, readout and PDUFA date, with drug type, therapeutic area and a PoA score you can trade on.
Institutional-grade data · Cancel anytime
PoA blends historical approval base rates, trial design score and FDA review track record.

CNTB Catalyst Timeline

Dated clinical, regulatory and corporate events for Connect Biopharma Holdings Limited

Catalyst Timeline

Dated clinical, regulatory & corporate events for Connect Biopharma Holdings Limited

242Total events
7Upcoming
65Tier-1 (high impact)
2021 to 2027Coverage

Upcoming catalysts 2

T3Interact Meeting
Subscribe to view catalyst details
Rademikibart
T2Quarterly Update
Subscribe to view catalyst details

Event history 50

●Quarterly UpdateCorporate
Reported third quarter 2026 financial results and business update
▲Secondary Endpoint DataRademikibartClinical Data
Rademikibart reduced new moderate to severe COPD exacerbations by 85% through Week 4
acute exacerbations in adults with COPD and type 2 inflammationsource ↗
▲Topline ReadoutRademikibartClinical Data
Positive preliminary topline data from global Phase 2 Seabreeze STAT COPD study of rademikibart
acute exacerbations in adults with COPD and type 2 inflammationsource ↗
▲Safety Data UpdateRademikibartClinical Data
Rademikibart well tolerated with lower incidence of adverse events than placebo
acute exacerbations in adults with COPD and type 2 inflammationsource ↗
▲Primary Endpoint MetRademikibartClinical Data
Rademikibart met primary endpoint, reducing treatment failure rate by 81% vs placebo through Week 4
acute exacerbations in adults with COPD and type 2 inflammationsource ↗
●R&D DayPresentation
Connect Biopharma to host conference call and webcast to discuss topline data
▲Topline ReadoutRademikibartClinical Data
Positive preliminary topline data from global Phase 2 Seabreeze STAT Asthma study of rademikibart
acute exacerbations in adult and adolescent participants with asthma and type 2 inflammationsource ↗
▼Primary Endpoint MissedRademikibartClinical Data
Primary endpoint of treatment failure at 28 days missed statistical significance (66% reduction; p=0.153)
acute exacerbations in adult and adolescent participants with asthma and type 2 inflammationsource ↗
▲Secondary Endpoint DataRademikibartClinical Data
Statistically significant improvement in post-bronchodilator FEV1 at Day 7 (250 mL vs 120 mL placebo; p=0.023)
acute exacerbations in adult and adolescent participants with asthma and type 2 inflammationsource ↗
▲Safety Data UpdateRademikibartClinical Data
Rademikibart well tolerated with no new safety signals; one SAE vs 3 SAEs in placebo arm
acute exacerbations in adult and adolescent participants with asthma and type 2 inflammationsource ↗
Unlock the full CNTB catalyst timeline
Every PDUFA date, readout, approval and corporate move, tiered by market impact and updated daily.
Institutional-grade data · Cancel anytime

Past FDA Catalysts and PDUFA Decisions

How CNTB actually traded into and out of each decision

Date Drug Catalyst Stage Reaction Event Move % Best Trade %
2026-09-30rademikibart Phase 2 topline data readout Phase 2
Unlock 7 more CNTB historical catalysts
Institutional-grade data · Cancel anytime
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision

Drug Pipeline Intelligence

Pipeline Score
Pipeline Value
Valuation Signal
3
Drugs Scored
rNPV / MCap
Top Drug
Top 58%
Micro Cap
(rank 417 of 719)
Percentile Rank
Showing 8 of 8 assets
DrugIndicationPhasePTRSrNPVStatusEnrollVelocityDesignEst. CompletionML SignalLast Change
CBP-201 Small MoleculesCompletedNCT04773678Moderate to Severe Persistent AsthmaPhase 2 COMPLETED 322Sep 28, 2023
Rademikibart BiologicsNCT06940141Asthma AcutePhase 2 COMPLETED 200Aug 10, 2026
Rademikibart BiologicsCompletedNCT06940154COPD Acute ExacerbationPhase 2 COMPLETED 159Aug 26, 2026
CBP-201 Small MoleculesCompletedNCT05017480Moderate-to-severe Atopic DermatitisPhase 2 COMPLETED 556Sep 28, 2023
Test drug: CBP-201 BiologicsCompletedNCT05917782UndisclosedPhase 1 COMPLETED 324Oct 6, 2023
CBP-307 Small MoleculesCompletedNCT04700449Moderate to Severe Ulcerative ColitisPhase 2 COMPLETED 145Nov 10, 2022
CBP-307 Small MoleculesCompletedNCT04818229Autoimmune DiseasesPhase 1 COMPLETED 176Mar 30, 2022
CBP-174 Small MoleculesCompletedNCT04811469UndisclosedPhase 1 COMPLETED 74May 21, 2022
Unlock the CNTB pipeline intelligence model
PTRS, rNPV, enrollment velocity, trial design quality and ML risk signals for every asset above.
Institutional-grade data · Cancel anytime

Clinical Trial Results

Readouts, endpoints and source filings for every CNTB program

Drug Name Indication Phase Date Trial Results SummaryTitleSource
rademikibart asthma and COPDPhase 22026-11-16250 mL increase in post-bronchodilator forced expiratory volume in one second (FEV1) at Day 7 compared to 120 mL with placebo (p=0.023); 100% reduction in hospital visits for COPD patients; 50% reduction in emergency department or unscheduled medical visits for worsening asthma symptoms versus placebo; 66% reduction in treatment failure rate over 28 days compared to placebo (p=0.153); 86% reduction in treatment failure rate using proposed entry criteria for Phase 3 program (p=0.0282)Read MoreConnect Biopharma Reports Third Quarter 2026 Financial Results and Provides Business UpdateRead More
Scroll for more · summaries link to the source press release
Unlock every CNTB trial readout
Institutional-grade data · Cancel anytime

Inside Trades

Unlock CNTB insider buying and selling
Monthly insider buys and sells against the stock price, with the insider sentiment reading.
Institutional-grade data · Cancel anytime
InsiderSideSharesPriceValueDate
Xanthopoulos Kleanthis GabrielDirectorGrant/Award 3,738 86,554 held$0.00 06/30/2026
Unlock the full CNTB insider trade log
Institutional-grade data · Cancel anytime

Hedge Fund 13F Activity

Fund % of Portfolio Current MV Shares Owned Activity
Ikarian Capital, LLC 0.2 % (-83.3 %) 2.46 M 2.24 M -50.74% ( -2.30 M)
Unlock every fund holding CNTB
Every 13F position with quarter over quarter share flow and average entry price.
Institutional-grade data · Cancel anytime
Unlock hedge fund flows in CNTB
Shares held by hedge funds each quarter, and who bought or sold.

Ownership Trends

Sign in to see CNTB ownership
Insider and institutional ownership, quarter by quarter.

CNTB Short Interest

Shares sold short, counted twice a month.

21.87%
Short % of Float
of tradable shares sold short
3.8M
Shares Sold Short
-0.7% vs prior count
4.2 Moderate
Days to Cover
trading days of normal volume to buy every short share back
913.7K
Avg Daily Volume
the average used for days to cover
Unlock CNTB short interest history
Two years of days to cover and shares sold short, with every count and its change.
Institutional-grade data · Cancel anytime

Options Data

Option Volume

Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg

Option Chain Statistics

ExpiryCall VolPut VolVol P/CCall OIPut OIOI P/CIV CallIV Call OI-WtdIV Call Vol-WtdIV PutIV Put OI-WtdIV Put Vol-Wtd
2026-12-18
Unlock CNTB option chain statistics
Per-expiry call and put volume, open interest, put-call ratios and implied volatility.
Institutional-grade data · Cancel anytime

Real-Time Option Chain

CallsStrikePuts
LastVolOILastVolOI
No data available
Unlock the live CNTB option chain
Live calls and puts by strike: last price, volume and open interest for every expiry.
Institutional-grade data · Cancel anytime

Calls vs Puts by Expiry

CallsPutsLog scale
Unlock CNTB options analytics
Institutional-grade data · Cancel anytime

Competitive positioning

How CNTB ranks across every disease it competes in

Competitive Position is a premium feature
See how CNTB ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial

CNTB News

CNTB
Nov 16, 2026
CNTBPhases
▼ -10%on this news

Connect Biopharma Reports Third Quarter 2026 Financial Results and Provides Business Update

Connect Biopharma reported positive preliminary data from its Phase 2 Seabreeze STAT studies for rademikibart, showing significant improvements in lung function for asthma and COPD patients. The company plans to discuss potential Phase 3 programs with the FDA in December 2026 and early 2027. Rademikibart demonstrated a 100% reduction in hospital visits for COPD patients.

Read more →
CNTB
Sep 30, 2026
CNTBPhases
▲ +10.9%on this news

Connect Biopharma Announces Positive Preliminary Topline Data from its Global Phase 2 Study of Rademikibart as an Add-on Treatment for Acute Exacerbations in Adults with COPD and Type 2 Inflammation

Connect Biopharma announced positive topline results from its Phase 2 study of rademikibart, showing significant reductions in treatment failure and COPD exacerbations. The drug demonstrated a 100% reduction in hospital visits for acute exacerbations and was well tolerated. The company plans to engage with the FDA for a Phase 3 program.

Read more →
CNTB
Sep 15, 2026
CNTBPhases
▼ -32.2%on this news

Connect Biopharma Announces Positive Preliminary Topline Data from its Global Phase 2 Study of Rademikibart as an Add-on Treatment for Acute Exacerbations in Adult and Adolescent Participants with Asthma and Type 2 Inflammation

Connect Biopharma announced positive topline results from its Phase 2 study of rademikibart, showing a 66% reduction in treatment failure for asthma exacerbations. The study demonstrated significant improvements in lung function within a week. The company plans to engage with the FDA for a Phase 3 program following additional data from a COPD study.

Read more →
CNTB
Sep 3, 2026
CNTBConferences/Events

Connect Biopharma to Present at the H.C. Wainwright 28th Annual Global Investment Conference

Connect Biopharma Holdings Limited will participate in the H.C. Wainwright 28th Annual Global Investment Conference on September 15, 2026. The company focuses on treatments for inflammatory diseases, particularly asthma and COPD, and is advancing its candidate rademikibart. An exclusive licensing agreement with Simcere Pharmaceutical for Greater China could yield substantial milestone payments.

Read more →
CNTB
Aug 12, 2026
CNTBPhases
▲ +9%on this news

Connect Biopharma Reports Second Quarter 2026 Financial Results and Provides Business Update

Connect Biopharma has completed enrollment in its Phase 2 Seabreeze STAT studies for asthma and COPD, with topline results anticipated in September 2026. The company reported a net loss of $17.3 million for the second quarter of 2026, while its cash runway is expected to last at least one year. Following the results, Connect plans to engage with the FDA regarding a potential Phase 3 program for rademikibart.

Read more →
CNTB
Jun 17, 2026
CNTBPhases

Connect Biopharma Announces Completion of Enrollment of Phase 2 Seabreeze STAT Asthma Study Evaluating Rademikibart for the Treatment of Acute Exacerbations in Asthma

Connect Biopharma has completed enrollment in its Phase 2 Seabreeze STAT Asthma study, which evaluates rademikibart for treating acute asthma exacerbations. The company expects to report topline data in early September 2026 and aims to finalize enrollment in the Seabreeze STAT COPD study soon. With a solid financial foundation, Connect is preparing to engage with the FDA regarding a Phase 3 program.

Read more →
CNTB
May 13, 2026
CNTBConferences/Events
▼ -8.6%on this news

Connect Biopharma to Present at the H.C. Wainwright 4th Annual BioConnect Investor Conference

Connect Biopharma Holdings Limited will participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference on May 19, 2026. The company is focused on developing rademikibart, a next-generation antibody for treating asthma and COPD. An archived replay of the presentation will be available for 90 days post-conference.

Read more →
CNTB
May 12, 2026
CNTBPhases
▲ +14.5%on this newsshared move

Connect Biopharma Reports First Quarter 2026 Financial Results and Provides Business Update

Connect Biopharma has reported its first-quarter financial results for 2026, indicating a net loss of $19.4 million. The company is progressing in its Phase 2 Seabreeze STAT studies for asthma and COPD, expecting topline data by mid-2026. A recent $20.2 million financing bolsters its operations, allowing for ongoing development of rademikibart, which has shown promising preliminary results. Despite financial challenges, management remains optimistic about the product's potential in the market.

Read more →
CNTB
Apr 23, 2026
CNTBPhases

Connect Biopharma Announces Enrollment in Phase 2 Seabreeze STAT Studies Will Continue as Planned Following Pre-Specified Interim Analysis - Expect to report topline data from both studies mid-2026

Connect Biopharma announced that enrollment in its ongoing Phase 2 Seabreeze STAT studies for rademikibart will proceed as planned. The independent Data Monitoring Committee confirmed the efficacy analysis without recommending any changes to sample size. Rademikibart continues to show positive tolerability among patients, and topline results are expected to be reported by mid-2026. The company is also aligning with the FDA for future Phase 3 program development.

Read more →
CNTB
Apr 1, 2026
CNTBGeneral

Connect Biopharma Reports 2025 Full-Year Financial Results and Provides Business Update

Connect Biopharma reported its 2025 financial results, highlighting significant progress in its lead drug candidate, rademikibart. The company released positive data from a Phase 1 study and is currently recruiting for Phase 2 studies aimed at asthma and COPD. Additionally, a $20.2 million equity financing was secured to support ongoing operations.

Read more →
CNTB
Mar 30, 2026
CNTBGeneral
▼ -15.9%on this newsshared move

Connect Biopharma Announces $20.2 Million Private Placement Financing

Connect Biopharma has announced a private placement financing of $20.2 million, which will extend its cash runway into the second half of 2027. The financing involves the sale of 6,130,000 shares at $3.25 each, led by its largest investor, Panacea Venture. The funds will support research and development of clinical-stage products and general corporate purposes.

Read more →
CNTB
Mar 30, 2026
CNTBPhases
▼ -15.9%on this newsshared move

Rademikibart Demonstrates Best-in-Class Potential in Phase 3 Atopic Dermatitis Study

Connect Biopharma announced positive results from a Phase 3 study of rademikibart for moderate-to-severe atopic dermatitis. The study demonstrated significant efficacy with ~90% of patients achieving near-maximal responses. Safety was comparable to placebo, with low rates of conjunctivitis. The findings were presented at the 2026 American Academy of Dermatology Annual Meeting.

Read more →
CNTB
Mar 30, 2026
CNTBPhases
▼ -15.9%on this newsshared move

Connect Biopharma Announces Positive Topline Data from its Phase 1 Study of Intravenous (IV) Rademikibart in Patients with Asthma or COPD

Connect Biopharma announced positive topline results from its Phase 1 study of intravenous rademikibart, showing rapid and sustained improvements in lung function for asthma and COPD patients. The study demonstrated significant FEV1 improvements as early as 15 minutes post-dosing, with effects maintained through Day 29. The company plans to advance to Phase 2 studies and engage with the FDA for a Phase 3 program.

Read more →
CNTB
Mar 10, 2026
CNTBPhases
▲ +5.3%on this news

Results from Phase 3 Study of Rademikibart in Moderate-to-Severe Atopic Dermatitis to be Presented in the Late-Breaking Research Session at the 2026 American Academy of Dermatology (AAD) Annual Meeting

Connect Biopharma announced that results from a Phase 3 study of rademikibart for moderate-to-severe atopic dermatitis will be presented at the 2026 AAD Annual Meeting. The study, conducted by Simcere Pharmaceutical, has shown promising results which may support the approval of Simcere's NDA in China. Connect Biopharma sees potential for rademikibart in treating atopic dermatitis beyond China.

Read more →
CNTB
Mar 3, 2026
CNTBConferences/Events

Connect Biopharma to Present at the Leerink Partners Global Healthcare Conference

Connect Biopharma Holdings Limited will participate in a fireside chat at the Leerink Partners Global Healthcare Conference on March 10, 2026. The event will be accessible via a live webcast, with an archived replay available for 90 days. The company is focused on developing rademikibart, a treatment for asthma and COPD, and has a licensing agreement with Simcere Pharmaceutical for the drug in Greater China.

Read more →
CNTB
Feb 19, 2026
CNTBConferences/Events

Connect Biopharma to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference

Connect Biopharma Holdings Limited will present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference on February 26, 2026. The company focuses on innovative treatments for inflammatory diseases, particularly asthma and COPD. They are advancing their therapy, rademikibart, which targets IL-4Rα and is currently undergoing global clinical trials. Connect has also established a collaboration with Simcere Pharmaceutical for the commercialization of rademikibart in Greater China.

Read more →
CNTB
Jan 12, 2026
CNTBPhases

Connect Biopharma Highlights New Mechanism of Action Data for Rademikibart and Outlines Priorities for 2026

Connect Biopharma has revealed new data supporting the unique mechanism of action for its drug rademikibart, highlighting its potential for rapid airway improvement. The company is currently recruiting patients for both Phase 1b and Phase 2 clinical studies targeting asthma and COPD, with topline results expected through mid-2026. Financially, Connect Biopharma has a solid cash position, likely sustaining operations through key clinical developments into 2027. Additional studies provide evidence of improved efficacy compared to existing treatments, suggesting rademikibart may effectively address significant unmet medical needs.

Read more →
CNTB
Nov 24, 2025
CNTBConferences/Events

Connect Biopharma to Present at the 8th Annual Evercore Healthcare Conference

Connect Biopharma Holdings Limited has announced its participation in the 8th Annual Evercore Healthcare Conference, scheduled for December 2nd, 2025. The company will engage in a fireside chat about its clinical-stage products, including rademikibart, designed to treat asthma and COPD. Connect is currently conducting global clinical studies and has licensed its product for distribution in Greater China. This involvement highlights the company's commitment to advancing treatment options in inflammatory diseases.

Read more →
CNTB
Nov 12, 2025
CNTBGeneral
▲ +5.9%on this news· ran to +64% by day 3

Connect Biopharma Reports Third Quarter 2025 Financial Results and Provides Business Update

Connect Biopharma reported a net loss of $40.4 million for the first nine months of 2025. The company holds $54.8 million in cash and expects funding to last through 2027. Simcere submitted a new drug application for rademikibart to treat atopic dermatitis in China. Connect also terminated its American Depositary Receipt program to list shares directly on Nasdaq.

Read more →
CNTB
Sep 29, 2025
CNTBPhases
▼ -16.6%on this news

Connect Biopharma Presents Data Supporting Rademikibart at the European Respiratory Society Congress 2025

Connect Biopharma presented data on rademikibart at the European Respiratory Society Congress 2025. The drug improved lung function by up to 507 mL in patients with high inflammatory markers. It also reduced asthma exacerbations by 63% to 69% in similar groups. The company expects to report topline data from its Seabreeze STAT studies in the first half of 2026.

Read more →

About Connect Biopharma Holdings Limited

San Diego, CA 64 employees connectbiopharm.com
Headquarters3580 CARMEL MOUNTAIN ROAD, SUITE 200, SAN DIEGO, CA, 92130
BIOPHARMAWATCH ELITE
Trade the next CNTB catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $24/mo billed annually.
Cancel anytime